Lyell Immunopharma, Inc. Common Stock
Compare this stock
LYEL Stock Report Card
$
43%
Performance
Score:
10/100
LYEL returned -58.96% in the last 12 months. Based on SPY's performance of -13.12%, its performance is below average giving it a score of 10 of 100.
Technicals
Score:
54/100
LYEL receives a 53 of 100 based on 14 indicators. 7 are bullish, 6 are bearish.
Earnings
Score:
100/100
LYEL has missed earnings 1 times in the last 20 quarters.
Profit
Score:
10/100
Out of the last 15 quarters, LYEL has had 0 profitable quarters and has increased their profits year over year on 0 of them.
Volatility
Score:
43/100
LYEL has had a lower than average amount of volatility over the last 12 months giving it a score of 43 of 100.
Lyell Immunopharma, Inc. Common Stock Summary
Nasdaq / LYEL
Healthcare
Biotechnology
Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845, that targets multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. The company entered into research and development collaboration and license agreement with GlaxoSmithKline for NY-ESO-1 program. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Checkout Similar Companies
LYEL scored poorly on our reportcard. Here are some similar companies and how they performed.
